SEOUL - Ildong Pharmaceutical Co. Ltd. and Cellivery Therapeutics Inc. have agreed to jointly research and develop a protein-based, cell-permeable anti-neurodegenerative disease agent using Cellivery's macromolecule intracellular transduction technology (MITT).
The therapy, iCP-Parkin, is set to enter preclinical trials, said officials at the two South Korean companies. It works to recover the functions of dopaminergic neurons and has so far...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?